cardura xl 4mg tableta s prodlouženým uvolňováním - search results

United States - English - NLM (National Library of Medicine)

cardura- doxazosin mesylate tablet cardura- doxazosin tablet

roerig - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg - cardura is indicated for the treatment of the signs and symptoms of bph. cardura is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive dru

United States - English - NLM (National Library of Medicine)

cardura xl- doxazosin mesylate tablet, multilayer, extended release cardura xl- doxazosin tablet, multilayer, extended release

roerig - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 4 mg - cardura® xl is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). cardura xl is not indicated for the treatment of hypertension. cardura xl is contraindicated in patients with a known hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any of the inert ingredients. allergic reactions to doxazosin and other quinazolines have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2) ]. risk summary cardura xl is not indicated for use in females and is not indicated for the treatment of hypertension. the limited available data with cardura xl in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of doxazosin to pregnant rats and rabbits at doses of up to 10 and 4 times, respectively, the 12 mg/day recommended dose. postnatal development was delayed in rats at a dose of 8 times the 12 mg/day recommended dose [see data]. data animal data radioactivity was found to cross the placenta following oral administration of labeled doxazosin to pregnant rats. studies in pregnant rabbits and rats at daily oral doses of up to 41 and 20 mg/kg, respectively (plasma drug concentrations of 10 and 4 times, respectively, the human auc exposures with a 12 mg/day therapeutic dose), during organogenesis have revealed no evidence of adverse developmental effects. a dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival. in peri- and postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin (about 8 times human auc exposure with a 12 mg/day therapeutic dose) was delayed, as evidenced by slower body weight gain and slightly later appearance of anatomical features and reflexes. risk summary cardura xl is not indicated for use in females and is not indicated for the treatment of hypertension. doxazosin is present in human milk. there is no information on the effects of cardura xl on the breastfeed infant or the effects on milk production. the safety and effectiveness of cardura xl in pediatric patients have not been established. the incidence of hypotension with cardura xl use appears to be age related and more prevalent in patients 70 years or older. at steady state, increases of 27% in maximum plasma concentrations (cmax ) and 34% in the area under the concentration-time curve (auc) were seen in the elderly (>65 years old) compared to the young [see clinical pharmacology (12.3) ]. of the 666 patients with bph who received cardura xl in the two controlled clinical efficacy and safety studies, 325 patients (49%) were 65 years of age or older. one hundred thirty-six patients treated with cardura xl (20%) were >70 years of age. in these two studies, the cumulative incidence of hypotension appeared to be age related. the reason for an increased incidence of hypotension in patients older than 70 years of age may be related to a modest increase in systemic exposure to doxazosin [see clinical pharmacology (12.3) ], to an increased propensity to orthostasis in the elderly, or to an enhanced sensitivity to vasodilatory agents in the elderly. the incidence of hypotension reported as an adverse reaction was higher in patients 70 years of age and older (4/136; 2.9%) as compared to patients < 70 years of age (7/530; 1.3%). since there is no clinical experience in patients with severe hepatic impairment, use in these patients is not recommended. cardura xl should be administered with caution to patients with mild or moderate hepatic impairment [see warnings and precautions (5.6), clinical pharmacology (12.3) ].

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

cardura xl 4mg tabletas de liberacion prolongada.

pfizer pharma pfe gmbh - doxazosina (mesilato) - doxazosina (mesilato)....4 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

cardura xl 4 mg tabletas de liberación prolongada

pfizer ofg germany gmbh - doxazosina (mesilato) - doxazosina (mesilato)....4.00 mg.

United States - English - NLM (National Library of Medicine)

cardura xl- doxazosin mesylate tablet, film coated, extended release

viatris specialty llc - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - cardura® xl is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). cardura xl is not indicated for the treatment of hypertension. cardura xl is contraindicated in patients with a known hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any of the inert ingredients. allergic reactions to doxazosin and other quinazolines have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2)] . cardura xl is not indicated for use in females and is not indicated for the treatment of hypertension. the limited available data with cardura xl in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of doxazosin to pregnant rats and rabbits at doses of up to 10 and 4 times, respectively, the 12 mg/day recommended dose. postnatal development was delayed in rats at a dose of 8 times the 12 mg/day recommended dose [see data] . radioactivity was found to cross the placenta following oral administration of labeled doxazosin to pregnant rats. studies in pregnant rabbits and rats at daily oral doses of up to 41 and 20 mg/kg, respectively (plasma drug concentrations of 10 and 4 times, respectively, the human auc exposures with a 12 mg/day therapeutic dose), during organogenesis have revealed no evidence of adverse developmental effects. a dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival. in peri- and postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin (about 8 times human auc exposure with a 12 mg/day therapeutic dose) was delayed, as evidenced by slower body weight gain and slightly later appearance of anatomical features and reflexes. cardura xl is not indicated for use in females and is not indicated for the treatment of hypertension. doxazosin is present in human milk. there is no information on the effects of cardura xl on the breastfeed infant or the effects on milk production. the safety and effectiveness of cardura xl in pediatric patients have not been established. the incidence of hypotension with cardura xl use appears to be age related and more prevalent in patients 70 years or older. at steady state, increases of 27% in maximum plasma concentrations (cmax ) and 34% in the area under the concentration-time curve (auc) were seen in the elderly (> 65 years old) compared to the young [see clinical pharmacology (12.3)] . of the 666 patients with bph who received cardura xl in the two controlled clinical efficacy and safety studies, 325 patients (49%) were 65 years of age or older. one hundred thirty-six patients treated with cardura xl (20%) were > 70 years of age. in these two studies, the cumulative incidence of hypotension appeared to be age related. the reason for an increased incidence of hypotension in patients older than 70 years of age may be related to a modest increase in systemic exposure to doxazosin [see clinical pharmacology (12.3)] , to an increased propensity to orthostasis in the elderly, or to an enhanced sensitivity to vasodilatory agents in the elderly. the incidence of hypotension reported as an adverse reaction was higher in patients 70 years of age and older (4/136; 2.9%) as compared to patients < 70 years of age (7/530; 1.3%). since there is no clinical experience in patients with severe hepatic impairment, use in these patients is not recommended. cardura xl should be administered with caution to patients with mild or moderate hepatic impairment [see warnings and precautions (5.6), clinical pharmacology (12.3)] .